The estimated Net Worth of Capital Partners L P Tyndall is at least $969 Mille dollars as of 24 September 2019. Capital Tyndall owns over 16,700 units of Onconova Therapeutics Inc stock worth over $616,389 and over the last 7 years Capital sold ONTX stock worth over $352,517.
Capital has made over 11 trades of the Onconova Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Capital sold 16,700 units of ONTX stock worth $19,873 on 24 September 2019.
The largest trade Capital's ever made was buying 10,147,058 units of Onconova Therapeutics Inc stock on 27 April 2018 worth over $4,363,235. On average, Capital trades about 953,912 units every 49 days since 2017. As of 24 September 2019 Capital still owns at least 616,389 units of Onconova Therapeutics Inc stock.
You can see the complete history of Capital Tyndall stock trades at the bottom of the page.
Capital's mailing address filed with the SEC is 150 EAST 58TH STREET, 14TH FLOOR, NEW YORK, NY, 10155.
Over the last 12 years, insiders at Onconova Therapeutics Inc have traded over $1,631,795 worth of Onconova Therapeutics Inc stock and bought 27,892,613 units worth $51,994,589 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Management, Llc 683 e Capital Partners L P Tyndall. On average, Onconova Therapeutics Inc executives and independent directors trade stock every 40 days with the average trade being worth of $294,478. The most recent stock trade was executed by Mark Patrick Guerin on 13 March 2024, trading 8,666 units of ONTX stock currently worth $8,666.
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has created an extensive library of targeted anti-cancer agents designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. onconova has three product candidates in clinical trials and six active pre-clinical programs. onconova seeks to develop products that improve the outcome for cancer patients by directly addressing the disease, its recurrence, and the burden of side-effects associated with current methods of treatment.
Onconova Therapeutics Inc executives and other stock owners filed with the SEC include: